Pharmaceuticals Inc. - Valeant Pharmaceuticals International Inc. Other Prominent Vendors - Abbott Laboratories Ltd. - Alcon Laboratories Inc. - Alimera Sciences Inc. - Allergan Inc. - Ampio Pharmaceuticals Inc. - Antisense Therapeutics Ltd. - Bausch
* Novartis: Alcon receives FDA approval of new multifocal intraocular lens to treat cataract patients in the United States Further company coverage: (Reporting By Zurich Slot)
Alcon benefits from leadership positions across eye care.
next 10 years, but it also extends the life cycle of in-house products as patents expire. Further, the acquisition of Alcon in 2011 greatly boosts Novartis' consumer and drug segments with additional sales from the fast-growing eye-care business
psoriasis drug AIN457 and hypertension drug LCZ696) will largely offset the patent losses. Novartis' eye-care business ( Alcon ) and generics unit (Sandoz) should help mitigate the patent losses as well.
be facing increased competition over the next several quarters. Outside the drug group, both the eye-care division of Alcon and the generic division of Sandoz posted gains of 6% and 4%, respectively, versus the prior-year period. We expect
deal are strategic acquisitions in the health and wellness space, and debt repayment. When Nestle sold its 52% stake in Alcon in 2010, it used the cash to cut its debt levels. Total debt/EBITDA fell from 1.5 times at the end of 2009 to 0
Outside the drug group, Novartis' remaining divisions posted slight declines, with the exception of a minor gain at the Alcon group. We believe manufacturing issues are weighing on consumer and generic drug sales. While resolutions to manufacturing
always has regulatory challenges from the payers. But the firm has a really superb franchise in its eye-care business, Alcon . Its pharmaceutical business is doing quite well. So when you look with the cash flows that the business generates, it
growth opportunity is reflected in the rich multiple Nestle is paying for the investment. When Nestle sold its stake in Alcon to Novartis NVS for $28 billion pretax, we argued that it should invest the cash in extending its footprint in emerging